Our scientific studies

The efficacy of Keranat™ was evaluated in two randomised, double-blind, placebo-controlled clinical studies.

The results showed that Keranat™ not only reduces hair loss, but also leaves hair healthier and shinier.

3 ex vivo studies
Mechanism of action

2 oral clinial studies

300 mg/day
1 capsule

120 women

Keranat™ mechanism of action

The Keranat™ mechanism of action is original because it acts on the biological motor of hair : the dermal papilla.

Excretion of IGF-1 growth factor

Researchers have shown that hair loss in women may be related to a lower level of IGF1, which is a growth factor secreted by the dermal papilla¹. IGF1 promotes cell multiplication in the bulb and regulates the hair cycle. In ex vivo tests, Keranat™ significantly increases the excretion of IGF1. As a result, cell proliferation in the bulb increases.

¹ R. Noordam,”Both low circulating insulin-like growth factor-1 and high-density lipoprotein cholesterol are associated with hair loss in middle-aged women” British Journal of Dermatology (2016) 175, pp728–734

Cell proliferation in the hair bulb

Keranat™ significantly stimulates cell proliferation in the bulb (+140%) cwhich is a good indicator of optimal hair growth.

Hair anchoring

Keranat™ increases the thickness of collagen in the connective tissue, which allows better hair anchoring.

Results of the oral clinical studies

Reduction of hair loss

Keranat™ significantly reduced hair loss after 12 weeks , compared to the placebo. This average reduction of 50% was measured by an objective and recognised method: the phototrichogram. Similarly, 91% of women observed a reduction in hair loss. (self-evaluation).

Hair shine and health

After 6 weeks, the dermatologist recorded that subjects who consumed Keranat™ had shinier, healthier hair.

After 12 weeks, hair was significantly shinier and healthier with Keranat™ compared to the placebo.

Similarly, after 12 weeks, 75% of women noticed that their hair was brighter, softer and suppler.

Reduced scalp dryness

After 6 weeks, the dermatologist recorded that scalp dryness was reduced reduced in subjects who consumed Keranat™. After 12 weeks, Keranat™ significantly reduces dryness of the scalp compared to the placebo.

The results of the studies have been published in peer-reviewed journals

S. Boisnic et al, Hair Therapy and Transplantation, 2016

“Miliacin associated with polar lipids : effect on growth factors excretion and extracellular matrix of the dermal papilla hair follicle model maintained in survival conditions”

M. Keophiphath et al, Journal of Cosmetic Dermatology, 2019

“Miliacin encapsulated by polar lipids stimulates cell proliferation in hair bulb and improves telogen effluvium in women”